コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ve therapy group (antiretroviral therapy and isoniazid preventive therapy).
2 CWs to be offered antiretroviral therapy and isoniazid preventive therapy.
3 r-randomized, phased-implementation trial of isoniazid preventive therapy.
4 in 7 years of follow-up for those initiating isoniazid preventive therapy.
5 tment; if not, they were offered 9 months of isoniazid preventive therapy.
6 afe initiation of antiretroviral therapy and isoniazid preventive therapy.
7 uld have greater confidence in the safety of isoniazid preventive therapy.
8 phases of a randomized, controlled trial of isoniazid preventive therapy.
9 or this purpose in assessing indications for isoniazid preventive therapy.
10 July 1992 and January 1994 and were offered isoniazid preventive therapy.
11 e test, 409 (50%) fit current guidelines for isoniazid preventive therapy, 84 (20%) we intended to tr
12 (95% CI 3.5-7.8) for empirical group and for isoniazid preventive therapy (95% CI 3.4-7.8); absolute
13 with HIV infection in Botswana receive daily isoniazid preventive therapy against tuberculosis withou
14 an help to prioritize active case finding or isoniazid preventive therapy among children exposed to T
15 tuberculosis was lower in participants given isoniazid preventive therapy and ART than participants g
16 se mortality was lower in participants given isoniazid preventive therapy and ART than participants g
17 f infected individuals who were eligible for isoniazid preventive therapy and the poor adherence with
18 6% received a medical examination, 91% began isoniazid preventive therapy, and 82% completed preventi
20 It is likely that antiretroviral therapy and isoniazid preventive therapy can be started safely in pe
21 nostics, reducing treatment delay, providing isoniazid preventive therapy continuously to human immun
23 f early TB was more effective than universal isoniazid preventive therapy, especially in children and
24 pregnant women with HIV infection to receive isoniazid preventive therapy for 28 weeks, initiated eit
26 creening, active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-20
27 gramme scenario, a combination of continuous isoniazid preventive therapy for individuals on antiretr
30 cident cases of tuberculosis; 37 were in the isoniazid preventive therapy group (2.3 per 100 person-y
31 y and empirical tuberculosis therapy) or the isoniazid preventive therapy group (antiretroviral thera
32 ncentrations in 19 of 662 individuals in the isoniazid preventive therapy group and ten of the 667 in
37 t would reduce early mortality compared with isoniazid preventive therapy in high-burden settings.
38 rculosis (MTB) infection and indications for isoniazid preventive therapy in HIV-infected persons.
39 omparing empirical tuberculosis therapy with isoniazid preventive therapy in HIV-positive outpatients
40 t reduce mortality at 24 weeks compared with isoniazid preventive therapy in outpatient adults with a
41 ion of systematic tuberculosis screening and isoniazid preventive therapy in outpatients with advance
44 med a phase I randomized controlled trial of isoniazid preventive therapy (IPT) before revaccination
46 The World Health Organization recommends isoniazid preventive therapy (IPT) for HIV-positive cont
49 Despite longstanding guidelines endorsing isoniazid preventive therapy (IPT) for people with HIV,
50 young child contacts (<5 years) who received isoniazid preventive therapy (IPT) had developed disease
51 sified tuberculosis case finding or prior to isoniazid preventive therapy (IPT) in patients infected
52 did not improve 24-week survival compared to isoniazid preventive therapy (IPT) in TB screen-negative
53 es and produced a high rate of completion of isoniazid preventive therapy (IPT) in those persons afte
54 y designed to compare the safety of starting isoniazid preventive therapy (IPT) in women living with
55 ty trial assessing the safety of 28 weeks of isoniazid preventive therapy (IPT) initiated during preg
64 ive tuberculin skin tests (TST) benefit from isoniazid preventive therapy (IPT) whereas those testing
65 annual follow-up examinations and secondary isoniazid preventive therapy (IPT), alone and in combina
66 early antiretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-in
71 protection against tuberculosis provided by isoniazid preventive therapy is not known for human immu
73 rticipants were randomly assigned to receive isoniazid preventive therapy (n=662) or placebo (n=667)
74 CI, 1.57 to 22.01; p = 0.009), self-reported isoniazid preventive therapy (odds ratio, 0.18; CI, 0.04
76 ly assigned (1:1) patients to receive either isoniazid preventive therapy or a placebo for 12 months
77 eligible pregnant women living with HIV for isoniazid preventive therapy or for further investigatio
78 T who were randomly assigned to either daily isoniazid preventive therapy plus ART or ART alone and f
80 d a community-based tuberculin screening and isoniazid preventive therapy project among high-risk inn
82 ultivariate algorithm that predicts benefit, isoniazid preventive therapy should be recommended to al
84 e if they had completed at least 5 months of isoniazid preventive therapy, unless they had completed
85 iduals to evaluate whether administration of isoniazid preventive therapy was effective in clearing M
87 supports efforts to further increase use of isoniazid preventive therapy with ART broadly among peop
88 no significant difference in the benefit of isoniazid preventive therapy with ART by sex, baseline C